Document:

<PAGE>

                                                                   EXHIBIT 10.16

                     MASTER LABORATORY SERVICES AGREEMENT

     THIS MASTER LABORATORY SERVICES AGREEMENT ("Agreement"), dated the 22nd day
of March 1999, when signed by both parties, will set forth the terms and
conditions between ADVANCED LIFE SCIENCES, an Illinois corporation with its
principal offices located at 12305 South New Avenue, Suite O, Lemont, IL 60439
("Sponsor") and MEDICHEM RESEARCH, INC., an Illinois corporation with its
principal offices located at 12305 South New Avenue, Lemont, IL 60439 ("MCR"),
under which MCR agrees to provide laboratory services to Sponsor as set forth
below.

Sponsor and MCR agree as follows:

1.   Services. MCR shall provide study planning consultation on laboratory
design, laboratory analysis, and/or data management services as requested by
Sponsor from time to time during the term of this Agreement. The specific
details of each assignment or task will be separately negotiated and specified
in writing on terms acceptable to the parties and otherwise subject to the terms
and conditions of this Agreement (each such writing, a Confirmation of Central
Laboratory Services ("CCLS")) in a document substantially in the form of
Appendix I to this Agreement.
----------

2.   Payment of Fees and Expenses.

     (a)  Each CLS shall contain a provisional services budget for the payment
of MCR's services to be performed pursuant to such CLS. Sponsor shall reimburse
MCR for all reasonable and necessary travel and lodging expenses incurred in the
performance of its services which have been requested or approved by Sponsor.

     (b)  Any special capital equipment that MCR is required to purchase to
conduct these services for Sponsor hereunder will be billed to Sponsor, provided
Sponsor has given its prior written consent to MCR.

     (c)  MCR will invoice Sponsor monthly or as separately agreed for services
rendered under any CLS and Sponsor shall pay all amounts of MCR's itemized
invoices for work completed according to terms agreed upon within each CLS.
Each invoice will reflect MCR's application of any amounts advanced by Sponsor.

3.   Term. This Agreement shall commence on the date of execution and shall
continue until terminated as hereinafter provided by either party.

4.   Confidentiality.

     (a)  It is understood that during the term of this Agreement and each CCLS,
MCR and its employees may be exposed to data and information which is
confidential and proprietary to Sponsor. All such data and information ("Sponsor
Confidential Information") made available, disclosed or otherwise made known to
MCR as a result of services under this Agreement or under any CCLS and
designated in writing as confidential shall be considered confidential and shall
be considered the sole property of Sponsor. All information regarding laboratory
services, laboratory management and all information regarding MCR's operations,
including but not limited to MCR Property (as defined in Section 5 below),
disclosed by MCR to Sponsor in connection with this Agreement or any CCLS is
proprietary, confidential information belonging to MCR (the "MCR Confidential
Information", and
<PAGE>

together with the Sponsor Information, the "Confidential Information"). The
Confidential Information shall be used by the receiving party and its employees
only for purposes of performing the receiving party's obligations hereunder or
under any CCLS. Each party agrees that it will not reveal, publish or otherwise
disclose the Confidential Information of the other party to any third party
without the prior written consent of the disclosing party.

     (b)  The foregoing obligations shall not apply to Confidential Information
which:

          (i)    is or becomes generally available to the public other than as a
                 result of a disclosure by the receiving party;

          (ii)   becomes available to the receiving party on a non-confidential
                 basis from a source which is not prohibited from disclosing
                 such information by a legal, contractual or fiduciary
                 obligation to the disclosing party;

          (iii)  the receiving party develops independently of any disclosure by
                 the disclosing party;

          (iv)   was in the receiving party's possession or known to the
                 receiving party prior to its receipt from the disclosing party;
                 or

          (v)    is required by law to be disclosed.

     (c)  This obligation of confidentiality and non-disclosure shall remain in
effect for a period of five years after the termination of this Agreement.

5.   Property Ownership.

     (a)  All data and information necessary for MCR to conduct project
assignments will be forwarded by Sponsor to MCR.

     (b)  All data and information generated or derived by MCR as the result of
services performed by MCR under this Agreement shall be and remain the exclusive
property of Sponsor. Any inventions that may evolve from the data and
information described above or as the result of services performed by MCR under
this Agreement shall belong to Sponsor, and MCR agrees to assign its rights in
any inventions and/or related patents to Sponsor.

     (c)  Notwithstanding the foregoing, Sponsor acknowledges that MCR possesses
certain inventions, processes, know-how, trade secrets, improvements, other
intellectual properties and other assets, including but not limited to
laboratory analyses, analytical methods, procedures and techniques, computer
technical expertise and software, which have been independently developed by MCR
without the benefit of any information provided by Sponsor (collectively MCR
Property"). Sponsor and MCR agree that any MCR Property or improvements thereto
which are used, improved, modified or developed by MCR under or during the term
of this Agreement or any CCLS are the product of MCR's technical expertise
possessed and developed by MCR prior to or during the performance of this
Agreement and are the sole and exclusive property of MCR. Sponsor further
acknowledges that MCR's professional staff possesses certain technical expertise
and conceptual expertise in area of laboratory services which have been
independently developed by MCR without the benefit of any information provided
by Sponsor. Sponsor and MCR agree that such technical expertise, processes,
methods, approach or analyses used, improved, modified or developed by MCR under
or during the term of the Agreement or any CCLS are the product of MCR's
technical
<PAGE>

expertise possessed and developed by MCR prior to the date of this Agreement and
are the sole and exclusive property of MCR.

6.   Regulatory Compliance; Inspection.

     (a)  In carrying out its responsibilities under this Agreement and each
CCLS, MCR agrees to assure that its services are conducted in substantial
compliance with all applicable laws, rules and regulations, including but not
limited to the U.S. Food, Drug and Cosmetic Act and the regulations promulgated
pursuant thereto, and with the standard of care customary in the central
laboratory industry.

     (b)  Sponsor warrants that neither any assignment or task requested by
Sponsor nor the conduct thereof as provided in this Agreement or in any CCLS
shall violate any applicable law or regulation. Sponsor shall nonfy MCR promptly
in writing of any FDA or other governmental inspection or inquiry concerning any
services being rendered by MCR or any study or project to which such services
relate.

     (c)  Neither MCR nor any of MCR's employees rendering services pursuant to
this Agreement is under investigation by the FDA for debarment action or is
presently debarred pursuant to the Generic Drug Enforcement Act of 1992. MCR
shall notify Sponsor immediately upon any inquiry concerning or the commencement
of any such proceeding concerning MCR or any such employee.

     (d)  If any governmental or regulatory authority conducts or gives notice
to MCR of its intent to conduct an inspection at MCR's facilities or take any
other regulatory action with respect to any study or services provided under
this Agreement, MCR will promptly give Sponsor notice thereof; including all
information pertinent thereto. Sponsor acknowledges that Sponsor may not direct
the manner in which MCR fulfills its obligations to permit inspection by
governmental entities. It shall not be a breach of this Agreement for MCR to
comply with the demands and requests of any governmental entity in accordance
with MCR's judgement or to fail to inform and consult with Sponsor before
complying with any such demand or request.

7.   Conflict of Interest. MCR represents and warrants to Sponsor that MCR is
not a party to any agreement which would prevent MCR from fulfilling its
obligations under this Agreement, and that during the term of this Agreement,
MCR will not enter into an agreement to provide services which would prevent MCR
from providing the services contemplated to be provided by MCR under this
Agreement or any CCLS.

8.   Indemnification.

     (a)  Sponsor shall defend, indemnify and hold harmless MCR, its affiliates
and their respective directors, officers, employees and agents (each, an
"Indemnified Party") from and against any and all losses, claims, actions,
damages, liabilities, costs and expenses, (including reasonable attorney's fees
and court costs) (collectively, "Losses"), joint or several, relating to or
arising from or in connection with this Agreement or any CCLS (including,
without limitation, any Losses arising from or in connection with any study,
test, product or potential product to which this Agreement or any CCLS relates)
or any litigation, investigation or other proceeding relating to any of the
foregoing, except to the extent such Losses are determined to have resulted
solely from gross negligence or intentional misconduct of the Indemnified Party
seeking indemnity hereunder.
<PAGE>

     (b)  MCR shall: (i) give Sponsor notice of any such claim or law suit
(including a copy thereof served upon MCR) within fifteen (15) days after such
claim or law suit was served upon MCR, (ii) cooperate with Sponsor and its legal
representatives in the investigation of any matter the subject of
indemnification, and (iii) not unreasonably withhold its approval of the
settlement of any such claim, liability or action by Sponsor that is the subject
of this Indemnification provision; provided, however, that MCR's failure to
comply with its obligations pursuant to this Section 8(b) shal1 not constitute a
breach of this Agreement or relieve Sponsor of Sponsor's indemnification
obligations pursuant to Section 8(a) above, except that such indemnification
obligations shall be relieved to the extent, if any, that Sponsor's defense of
the affected claim, action or proceeding actually was impaired materially
thereby.

     (c)  If for any reason the foregoing indemnity is unavailable to any
Indemnified Party or is otherwise insufficient to hold such Indernnified Party
harmless, Sponsor shall contribute to the amount paid or payable by such
Indemnified Party as a result of such loss in such proportion as is appropriate
to reflect the relative benefits received by Sponsor and MCR and the relative
fault of Sponsor and MCR or such other Indemnified Party, as well as any other
relevant equitable considerations, subject in all cases to the limitation that
in no event shall the collective, aggregate contribution of all Indemnified
Parties to all Losses with respect to which contribution is available hereunder
exceed the amount of compensation actually received by MCR from Sponsor pursuant
to this Agreement for the assignment or task from which such Loss arose.

9.   Limitation of Liability. Neither MCR nor its affiliates nor any of its or
their respective directors, officers, employees or agents shall have any
liability whatsoever under this Agreement or otherwise except with respect to
damages directly attributable solely to MCR's gross negligence, intentional
misconduct, or breach of this Agreement. Notwithstanding the foregoing, neither
MCR nor its affiliates nor any of its or their respective directors, officers,
employees or agents shall have any liability for any special, incidental, or
consequential damages, including, but not limited to the loss of opportunity,
loss of the use of any data or information supplied hereunder, or loss of
revenue or profit in connection with or arising out of this Agreement or any
CCLS, the services performed by MCR hereunder or thereunder or the existence,
furnishing, functioning, or Sponsor's use of any information, documentation or
services provided pursuant to this Agreement or any CCLS, even if MCR shall have
been advised of the possibility of such damages. In addition, in no event shall
the collective, aggregate liability of MCR and its affiliates and their
respective directors, officers, employees and agents under this Agreement exceed
the amount of compensation actually received by MCR from Sponsor pursuant to
this Agreement for the assignment or task from which such liability arose.

10.  Review of Work. During the term of this Agreement and each CCLS, MCR will
permit Sponsor's representative(s) to examine the work performed hereunder and
the specific facilities at which the work is conducted during regular business
hours after reasonable notice and in a reasonable manner to determine that the
project assignment is being conducted in accordance with the applicable CCLS and
that the facilities are adequate; provided, however, that all information
disclosed or revealed to or ascertained by Sponsor in connection with any such
examination shall be deemed to constitute MCR Confidential Information for
purposes of this Agreement.

11.  Publication. Publication of project assignment results, in whole or in
part, shall be within the sole and absolute discretion of Sponsor. Results may
not be published or referred to, in whole or in part, without the prior written
consent of Sponsor.
<PAGE>

12.  Termination.

     (a)  This Agreement or any CCLS may be terminated with or without cause by
Sponsor or by MCR at any time during the term of this Agreement on ninety (90)
days prior written notice to MCR or Sponsor, as appropriate.

     (b)  Termination of this Agreement shall constitute termination of all
CCLSs hereunder. Termination of a CCLS shall constitute a termination of such
CCLS only and shall not affect this Agreement or any other CCLSs outstanding
hereunder.

     (c)  In the event this Agreement is terminated, Sponsor shall pay to MCR:
(i) any fees for services rendered then due and owing to MCR because of any
performance of MCR's obligations hereunder; (ii) all actual costs to complete
activities associated with the termination and close out of projects; and (iii)
all kit destruction costs as noted in each CCLS. Upon the termination of this
Agreement, MCR shall deliver to Sponsor all data and materials provided by
Sponsor to MCR for the conduct of services under this Agreement.

     (d)  In the event this Agreement is terminated, MCR reserves the right to
retain one copy of all material provided by or to Sponsor as the result of or in
connection with services performed by MCR under this Agreement or under any
CCLS, which copy will remain sealed unless a dispute arises regarding the
services performed by MCR hereunder or thereunder,

     (e)  Termination of this Agreement or any CCLS hereunder shall not
constitute a release or waiver of any right or remedy available to either party
in connection herewith or therewith.

13.  Independent Contractor Relationship. Notwithstanding any provision herein
to the contrary, the parties hereto are independent contractors.  MCR
acknowledges that it will render services to Sponsor as an independent
contractor and that MCR is not an employee of Sponsor.

14.  Insurance.

     (a)  As an independent contractor, any personal injury or property damage
suffered by MCR, its officers, directors, agents and employees in the course of
carrying out any duties under this Agreement will be MCR's sole responsibility,
except to the extent such personal injury or property damage occurs on Sponsor's
premises and is caused by Sponsor's negligence.

     (b)  No workers' compensation insurance shall be obtained by Sponsor
concerning MCR.  MCR shall comply with workers' compensation laws and shall
provide a certificate of workers' compensation insurance, where applicable.

15.  Force Majeure and Related Matters. MCR shall not be liable or responsible
to Sponsor nor be deemed to have defaulted under or breached this Agreement or
any CCLS for or in respect of errors, delays or other consequences arising from
Sponsor's failure to provide documents, materials, information or cooperation
required
<PAGE>

by MCR in order to perform properly and timely MCR's obligations hereunder or
thereunder. Any delay in the performance of any of the duties or obligations of
either party hereto (except the payment of money owed) shall not be considered a
breach of this Agreement and the time required for performance shall be extended
for a period equal to the period of such delay, provided that such delay has
been caused by or is the result of any labor disputes, including strikes,
lockouts, job actions or boycotts; inability to procure materials; riots;
insurrection; embargoes; war; acts of God; acts of the public enemy; inclement
weather; fires; explosions; floods or other natural disasters; or other reasons
or causes beyond the reasonable control of the party seeking to perform. The
party so affected shall give prompt notice to the other party of such cause and
shall take whatever reasonable steps are necessary to relieve the effect of such
cause as rapidly as possible.

16.  Notices. Any notice required or permitted to be given by either party
hereunder shall be in writing and shall be deemed given on the date received if
delivered personally or three days after the date postmarked if sent by
registered or certified U.S. mail, return receipt requested, postage prepaid or
by nationally recognized overnight delivery service to the following addresses:

     If to MCR:          Sarawak Medichem Research, Inc.
                         12305 South New Avenue
                         Lemont, IL 60439
                         Attn:  John L. Flavin

     If to Sponsor:      Advanced Life Sciences
                         12305 South New Avenue, Suite O
                         Lemont, IL 60439
                         Attn:  Michael T. Flavin, Ph.D.

17.  Miscellaneous.

     (a)  Governing Law. This Agreement and each CCLS shall be construed,
interpreted in accordance with and enforced under the laws of the State of
Illinois, without regard to the conflict of laws provisions thereof.  If any one
or more provisions of this Agreement or any CCLS shall be found to be illegal or
unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.

     (b)  Survival. The obligations of the parties contained in Sections 4, 8, 9
and 11 shall survive the termination of this Agreement.

     (c)  Entire Agreement; Amendments. This Agreement, together with each CCLS,
contains the entire understanding of the parties with respect to the subject
matter herein, and supersedes all previous agreements (oral and written),
negotiations and discussions. The parties may modify or amend the provisions
hereof only by an instrument in writing duly executed by the parties.

     (d)  Binding Agreements and Assignment. This Agreement shall be binding
upon and inure to the benefit of Sponsor and MCR and their respective successors
and permitted assigns. Neither this Agreement nor any
<PAGE>

of either party's rights hereunder may be assigned or otherwise transferred by
either party without the prior written consent of the other; provided, however,
                                                             --------  -------
MCR may in its sole discretion assign at any time any or all of its rights and
obligations under this Agreement to any of its corporate affiliates or may
utilize any such affiliates to carry out its obligations under this Agreement.

     (e)  Waiver. No waiver by either party of any breach of any provision of
this Agreement or any CCLS shall constitute a waiver of any other or subsequent
breach.

     (f)  Headings. The descriptive headings of the sections of this Agreement
are inserted for convenience only and shall not control or affect the meaning or
construction of any provision hereof.

     (g)  Incorporation by Reference. All exhibits attached hereto shall be
deemed to be incorporated herein. In case of any conflict between this Agreement
and any such attachment, the terms of this Agreement shall prevail over the
attachment.

     IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto
through their duly authorized officers on the date(s) set forth below.

MEDICHEM RESEARCH, INC.                           ADVANCED LIFE SCIENCES

By:________________________                       By:__________________________
     John L. Flavin

Title: Vice President, Contractual Operations     Title:

Date:_______________________                      Date:________________________<PAGE>

                                                                   EXHIBIT 10.17

                                   AGREEMENT
                                   ---------

In this agreement, made and entered into as of the 31 day of August, 1999
("Effective Date"), MediChem Research, Inc., an Illinois corporation
("MediChem") and Advanced Life Sciences, Inc., and Illinois corporation ("ALS"),
agree as follows:

1.  MediChem has acquired a license (attached as Appendix B) to the patent
    entitled "Methods for Screening Chromatographic Adsorbents" (Application
    60/070,887) filed on January 9, 1998 ("Patent"). To the best of MediChem's
    knowledge, the Patent is owned by Regis Technologies, Inc.

2.  ALS desires to acquire and MediChem is willing to assign to ALS all of
    MediChem's rights, interests and obligations to the technical information
    pursuant to section 4.1 of the license of Appendix B.

3.  ALS desires to acquire and MediChem is willing to sublicense to ALS all of
    MediChem's rights, interests and obligations to any and all patents that
    accrue from the technical information pursuant to section 4.1 of the license
    of Appendix B.

4.  MediChem hereby transfers, grants, conveys, assigns, and relinquishes
    exclusivity to ALS all of MediChem's rights, interests and obligations to
    the technical information and any patents accruing from the technical
    information set forth in the license of Appendix B.

5.  MediChem hereby transfers, grants, conveys, and relinquishes exclusivity to
    ALS the right to sublicense, in part or in whole, the technical information
    and any patents accruing from the technical information set forth in the
    license of Appendix B. Furthermore, ALS herewith grants MediChem an
    exclusive sublicense attached hereto as Appendix A.

6.  On the Effective Date, ALS shall pay to MediChem the lump sum payment of
    $75,000.00 as specified by ALS.

7.  In furtherance of this Agreement, MediChem hereby acknowledges that, from
    the Effective Date forward, ALS has succeeded to all of MediChem's rights,
    interests and obligations under the Appendix B license.

8.  MediChem represents and warrants that no consents of other parties are
    necessary or appropriate under any agreements in order for the assignment
    under this agreement to be legally effective.

9.  This agreement shall inure to the benefit of, and be binding on, the parties
    hereto together with their respective legal representatives, successors and
    assigns.

10. This agreement merges and supercedes all prior and contemporaneous
    agreements, assurances, representations, and communications between or among
    the parties hereto concerning the matters set forth herein.
<PAGE>

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be
executed by its duly authorized officer or representative as of the date set
forth below.

Advanced Life Sciences, Inc.                    MediChem Research, Inc.

____________________________                    __________________________
Michael T. Flavin, Ph.D.                        Jeffrey A. Whitnell
President                                       Chief Financial Officer

____________________________                    __________________________
Date                                            Date
<PAGE>

                              APPENDIX A

                          LICENSE AGREEMENT

    In this Agreement, made and entered into as of the 31 day of August, 1999
("Effective Date"), Advanced Life Sciences, Inc., ("Licensor") hereby grants an
exclusive sublicense to MediChem Research, Inc., ("Licensee") under the express
terms and conditions of the License Agreement between MediChem Research Inc.,
and Regis Technologies, Inc., attached hereto as Appendix B.

    Furthermore, Licensor agrees to the following provision:

1.  Royalties & Milestones

    1.1  Licensee will pay Licensor a royalty of four percent (4%) of all
    Net Sales of any of the Licensed Products.

    1.2 Licensor agrees to pay Licensee a milestone payment of $300,000.00 upon
    demonstrated Commercial Use.

    1.3 Licensor agrees to pay Licensee a milestone payment of $300,000.00 upon
    successful issuance of the Licensed Patent from the United States Patent and
    Trademark Office.

    1.4 Licensor agrees to pay Licensee a milestone payment of $150,000.00 for
    each publication in a Peer Reviewed Journal.

Advanced Life Sciences, Inc.                     MediChem Research, Inc.

___________________________                      ____________________________
Michael T. Flavin, Ph.D.                         Jeffrey A. Whitnell
President                                        Chief Financial Officer

___________________________                      ____________________________
Date                                             Date
<PAGE>

                                   EXHIBIT A

What is claimed is:
     1.  A method for identifying a selective adsorbent for separating analyte
         mixtures comprising:
         a.  providing an array of containers each having a candidate selective
             adsorbent;
         b.  adding a solution of the analyte mixture to be separated to each
             selective adsorbent candidate in the containers;
         c.  allowing the analyte mixture to interact with the selective
             adsorbent candidate; and
         d.  identifying the distribution of analyte mixture in the solution or
             on the selective adsorbent candidate.

     2.  The method of claim 1 wherein the selective adsorbent is silica having
         an organic molecule covalently linked thereto.

     3.  The method of claim 1 wherein the selective adsorbent is polystyrene
         having an organic molecule covalently linked thereto.

     4.  The method of claim 2 wherein the selective adsorbent is derived from
         silica having an aminoalkyl group covalently linked thereto.

     5.  The method of claim 4 wherein the aminoalkyl group has at least one
         enantioenriched amino acid covalently linked thereto.

     6.  The method of claim 1 wherein the amount of selective adsorbent is
         about 1 mg to 100 mg.

     7.  The method of claim 1 wherein the analyte mixture is tested in an array
         of 50-1000 candidate selective adsorbents.

     8.  The method of claim 1 wherein the distribution of analytes is measured
         by high pressure liquid chromatography or gas chromatography.

     9.  The method of claim 8 wherein chromatographic detection by mass
         spectrometry is employed.

     10. The method of claim 8 wherein an aliquot of the analyte mixture is
         removed and subjected to chemical derivatization prior to analysis.

     11. The method according to claim 1 wherein the analyte mixture is a
         mixture of enantiomers.

     12. The method of claim 1 wherein the distribution of analytes is measured
         by chiroptical spectroscopy techniques such as circular dichroism
         spectroscopy or measurement of optical rotation.
<PAGE>

ABSTRACT OF THE DISCLOSURE

     The invention discloses a method for rapid identification of a candidate
selective separation material by placing small samples of the candidate material
in an array of vials and adding a solution of the analytes to be separated. The
solution is allowed to interact or equilibrate and the distribution of the
analytes in the solid or liquid phase is measured usually by gas or liquid
chromatography. The identified candidate material with the greatest differential
adsorption of the analytes is selected and used as an adsorbent for large scale
separation. The rapid screening of chromatographic adsorbents provides an
efficient way of finding suitable absorbent materials for large scale
separations.
<PAGE>

                                   APPENDIX B

                               SEE EXHIBIT 10.13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}]]